The primary objective of the study is to evaluate the pharmacokinetics of healthy Chinese volunteers after oral administration of SHR1459 tablets in new and old formulations. The secondary objective of the study is to evaluate the safety after single dose of SHR1459 orally in healthy Chinese subjects.
The PK parameters (AUC0-t, AUC0-inf, Cmax, Tmax, T1/2z, CL/F and Vz/F etc.) will be calculated to evaluate the pharmacokinetics of healthy Chinese volunteers after oral administration of SHR1459 tablets in new and old formulations. During the study, the safety will be assessed by vital signs, physical examination, laboratory examination (hematology, blood biochemistry, urinalysis, coagulation examination), 12-lead electrocardiogram. The incidence and severity degree of adverse events and severe adverse events will be evaluated based on CTCAE 5.0.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
28
TR group: The first period,the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout; The second period,the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h. RT group: The first period,the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout; The second period,the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h.
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Pharmacokinetics parameter: Cmax of SHR1459
Peak plasma concentration (Cmax)of SHR1459
Time frame: through study completion, an average of 29 days
Pharmacokinetics parameter: AUC of SHR1459
Area under the plasma concentration versus time curve (AUC)of SHR1459
Time frame: through study completion, an average of 29 days
Pharmacokinetics parameter: Tmax of SHR1459
Time of maximum observed concentration (Tmax) of SHR1459
Time frame: through study completion, an average of 29 days
Pharmacokinetics parameter: T1/2z of SHR1459
Half time (T1/2z) of SHR1459
Time frame: through study completion, an average of 29 days
Pharmacokinetics parameter: CL/F of SHR1459
Total body clearance for extravascular administration (CL/F) of SHR1459
Time frame: through study completion, an average of 29 days
Pharmacokinetics parameter: Vz/F of SHR1459
Volume of distribution (Vz/F) of SHR1459
Time frame: through study completion, an average of 29 days
The number of participants with treatment-related adverse events as assessed by CTCAE v5.0
An adverse event is any untoward medical occurrence in a patient or clinical study participant
Time frame: through study completion, an average of 29 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.